Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 17, 2023

SELL
$36.12 - $41.79 $2,672 - $3,092
-74 Reduced 1.04%
7,029 $257,000
Q1 2023

Apr 12, 2023

SELL
$39.39 - $51.28 $338,754 - $441,008
-8,600 Reduced 54.77%
7,103 $289,000
Q4 2022

Jan 11, 2023

SELL
$41.75 - $54.5 $24,799 - $32,373
-594 Reduced 3.64%
15,703 $0
Q1 2022

May 04, 2022

BUY
$45.75 - $56.69 $183,000 - $226,760
4,000 Added 32.53%
16,297 $844,000
Q4 2021

Jan 21, 2022

SELL
$41.32 - $61.25 $82,061 - $121,642
-1,986 Reduced 13.9%
12,297 $726,000
Q3 2021

Nov 04, 2021

BUY
$39.25 - $50.42 $2,904 - $3,731
74 Added 0.52%
14,283 $614,000
Q2 2021

Aug 02, 2021

BUY
$35.91 - $40.68 $359 - $406
10 Added 0.07%
14,209 $556,000
Q1 2021

Apr 30, 2021

SELL
$33.49 - $37.77 $279,574 - $315,303
-8,348 Reduced 37.02%
14,199 $514,000
Q4 2020

Feb 05, 2021

BUY
$33.47 - $42.56 $9,706 - $12,342
290 Added 1.3%
22,547 $829,000
Q1 2020

Apr 27, 2020

BUY
$27.03 - $38.62 $332,090 - $474,485
12,286 Added 123.22%
22,257 $726,000
Q4 2019

Jan 16, 2020

SELL
$32.92 - $37.36 $32,097 - $36,426
-975 Reduced 8.91%
9,971 $391,000
Q3 2019

Oct 16, 2019

BUY
$32.49 - $42.13 $3,996 - $5,181
123 Added 1.14%
10,946 $393,000
Q2 2019

Jul 25, 2019

SELL
$36.98 - $41.52 $3,106 - $3,487
-84 Reduced 0.77%
10,823 $469,000
Q1 2019

Apr 11, 2019

BUY
$37.5 - $41.2 $3,150 - $3,460
84 Added 0.78%
10,907 $463,000
Q4 2018

Feb 06, 2019

SELL
$38.47 - $43.86 $10,194 - $11,622
-265 Reduced 2.39%
10,823 $472,000
Q1 2018

Apr 19, 2018

SELL
$31.91 - $37.02 $319 - $370
-10 Reduced 0.09%
11,088 $394,000
Q4 2017

Feb 16, 2018

BUY
$33.26 - $35.29 $249,283 - $264,498
7,495 Added 208.02%
11,098 $402,000
Q3 2017

Oct 18, 2017

BUY
$31.0 - $34.15 $111,693 - $123,042
3,603
3,603 $129,000

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $166B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track D. Scott Neal, Inc. Portfolio

Follow D. Scott Neal, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. Scott Neal, Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. Scott Neal, Inc. with notifications on news.